Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Hematol ; 104(4): 491-501, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27380194

ABSTRACT

Iron overload remains a concern in myelodysplastic syndrome (MDS) patients. Iron chelation therapy (ICT) thus plays an integral role in the management of these patients. Moreover, ICT has been shown to prolong leukemia-free survival in MDS patients; however, the mechanisms responsible for this effect are unclear. Iron is a key molecule for regulating cytosolic aconitase 1 (ACO1). Additionally, the mutation of isocitrate dehydrogenase (IDH), the enzyme downstream of ACO1 in the TCA cycle, is associated with epigenetic abnormalities secondary to 2-hydroxyglutarate (2-HG) and DNA methylation. However, epigenetic abnormalities observed in many MDS patients occur without IDH mutation. We hypothesized that iron itself activates the ACO1-IDH pathway, which may increase 2-HG and DNA methylation, and eventually contribute to leukemogenesis without IDH mutation. Using whole RNA sequencing of bone marrow cells in iron-overloaded mice, we observed that the enzymes, phosphoglucomutase 1, glycogen debranching enzyme, and isocitrate dehydrogenase 1 (Idh1), which are involved in glycogen and glucose metabolism, were increased. Digital PCR further showed that Idh1 and Aco1, enzymes involved in the TCA cycle, were also elevated. Additionally, enzymatic activities of TCA cycle and methylated DNA were increased. Iron chelation reversed these phenomena. In conclusion, iron activation of glucose metabolism causes an increase of 2-HG and DNA methylation.


Subject(s)
Bone Marrow/metabolism , DNA Methylation/drug effects , Iron Regulatory Protein 1/metabolism , Iron/pharmacology , Isocitrate Dehydrogenase/metabolism , Animals , Carcinogenesis/chemically induced , Glucose/metabolism , Glutarates/blood , Iron Regulatory Protein 1/drug effects , Isocitrate Dehydrogenase/drug effects , Mice
2.
J Neurosci Res ; 83(8): 1601-10, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16568477

ABSTRACT

Manganese (Mn) is an essential trace element, though at elevated exposures it is also a neurotoxicant. Several mechanisms underlying manganese toxicity have been investigated, although a consistent mechanism(s) of action at low exposures has not been fully elucidated. Here we systematically evaluated the effects of in vitro manganese exposure on intracellular iron (Fe) homeostasis and iron-regulatory protein (IRP) binding activity in undifferentiated PC12 cells over a range of manganese exposure concentrations (1, 10, 50, and 200 microM MnCl(2)) and exposure durations (12, 24, 36, and 48 hr), to test the hypothesis that moderately elevated manganese exposure disrupts cellular iron regulation. Results demonstrate that manganese exposure produces a rapid and sustained dose-dependent dysregulation of cellular iron metabolism, with effects occurring as early as 12 hr exposure and at manganese doses as low as 1 microM. Manganese exposure altered the dynamics of IRP-1 binding and the intracellular abundance of IRP-2, and altered the cellular abundance of transferrin receptor, ferritin, and mitochondrial aconitase protein levels. Cellular levels of labile iron were significantly increased with manganese exposure, although total cellular iron levels were not. The overall pattern of effects shows that manganese produced an inappropriate cellular response akin to iron deficiency, to which the cells were able to mount a compensatory response. Consistent with our previous studies, these data indicate that even low to moderate exposures to Manganese in vitro significantly disrupt cellular iron metabolism, which may be an important contributory mechanism of manganese neurotoxicity.


Subject(s)
Iron/metabolism , Manganese Poisoning/metabolism , Manganese/toxicity , Neurotoxins/toxicity , Aconitate Hydratase/metabolism , Animals , Brain/drug effects , Brain/metabolism , Brain/physiopathology , Dose-Response Relationship, Drug , Ferritins/drug effects , Ferritins/metabolism , Intracellular Fluid/drug effects , Intracellular Fluid/metabolism , Iron Regulatory Protein 1/drug effects , Iron Regulatory Protein 1/metabolism , Iron Regulatory Protein 2/drug effects , Iron Regulatory Protein 2/metabolism , Magnesium Chloride/toxicity , Mitochondria/drug effects , Mitochondria/metabolism , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , PC12 Cells , Protein Binding/drug effects , Protein Binding/physiology , Rats , Receptors, Transferrin/drug effects , Receptors, Transferrin/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...